Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

C-KIT Receptor Inhibition as a Promising Approach to Design Anticancer Drugs

Author(s): Igor José dos Santos Nascimento* and Ricardo Olimpio de Moura

Volume 30, Issue 24, 2023

Published on: 23 January, 2023

Page: [2702 - 2704] Pages: 3

DOI: 10.2174/0929867330666230111110537

Price: $65

« Previous Next »
[1]
Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin., 2022, 72(1), 7-33.
[http://dx.doi.org/10.3322/caac.21708] [PMID: 35020204]
[2]
Guti, E.; Regdon, Z.; Sturniolo, I.; Kiss, A.; Kovács, K.; Demény, M.; Szöőr, Á.; Vereb, G.; Szöllősi, J.; Hegedűs, C.; Polgár, Z.; Virág, L. The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC. Cancer Immunol. Immunother., 2022, 71(9), 2151-2168.
[http://dx.doi.org/10.1007/s00262-022-03146-z] [PMID: 35066605]
[3]
Santos-Junior, P.F. da S.; Nascimento, I.J. dos S.; da Silva, E.C.D.; Monteiro, K.L.C.; de Freitas, J.D.; de Lima Lins, S.; Maciel, T.M.S.; Cavalcanti, B.C.; V. Neto, J. de B.; de Abreu, F.C.; Figueiredo, I.M.; Carinhanha C. Santos, J.; Pessoa, C. do Ó; da Silva-Júnior, E.F.; de Araújo-Júnior, J.X.; M. de Aquino, T. Synthesis of hybrids thiazole–quinoline, thiazole–indole and their analogs: In vitro anti-proliferative effects on cancer cell lines, DNA binding properties and molecular modeling. New J. Chem., 2021, 45, 13847-13859.
[http://dx.doi.org/10.1039/D1NJ02105B]
[4]
Hadianamrei, R.; Tomeh, M.A.; Brown, S.; Wang, J.; Zhao, X. Rationally designed short cationic α-helical peptides with selective anti-cancer activity. J. Colloid Interface Sci., 2022, 607(Pt 1), 488-501.
[http://dx.doi.org/10.1016/j.jcis.2021.08.200] [PMID: 34509120]
[5]
Li, L.; Li, P.; Song, H.; Ma, X.; Zeng, S.; Peng, Y.; Zhang, G. Targeting entry into mitochondria for increased anticancer efficacy of BCL-XL-selective inhibitors in lung cancer. Pharmacol. Res., 2022, 177, 106095.
[http://dx.doi.org/10.1016/j.phrs.2022.106095] [PMID: 35074525]
[6]
Ashman, L.K.; Griffith, R. Therapeutic targeting of c-KIT in cancer. Expert Opin. Investig. Drugs, 2013, 22(1), 103-115.
[http://dx.doi.org/10.1517/13543784.2013.740010] [PMID: 23127174]
[7]
Medinger, M.; Drevs, J. Receptor tyrosine kinases and anticancer therapy. Curr. Pharm. Des., 2005, 11(9), 1139-1149.
[http://dx.doi.org/10.2174/1381612053507611] [PMID: 15853662]
[8]
Wu, T.S.; Lin, W.H.; Tsai, H.J.; Hsueh, C.C.; Hsu, T.; Wang, P.C.; Lin, H.Y.; Peng, Y.H.; Lu, C.T.; Lee, L.C.; Tu, C.H.; Kung, F.C.; Shiao, H.Y.; Yeh, T.K.; Song, J.S.; Chang, J.Y.; Su, Y.C.; Chen, L.T.; Chen, C.T.; Jiaang, W.T.; Wu, S.Y. Discovery of conformational control inhibitors switching off the activated c-KIT and targeting a broad range of clinically relevant c-KIT mutants. J. Med. Chem., 2019, 62(8), 3940-3957.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01845] [PMID: 30968693]
[9]
Pathania, S.; Pentikäinen, O.T.; Singh, P.K. A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors. Biochim. Biophys. Acta Rev. Cancer, 2021, 1876(2), 188631.
[http://dx.doi.org/10.1016/j.bbcan.2021.188631] [PMID: 34606974]
[10]
Tavares, F.M.; Gomes, A.C.; Assunção, E.M.; de Medeiros, J.L.S.; Scotti, M.T.; Scotti, L.; Ishiki, H.M. Virtual screening and molecular docking: Discovering novel c-KIT inhibitors. Curr. Med. Chem., 2022, 29(2), 166-188.
[http://dx.doi.org/10.2174/0929867328666210915102920] [PMID: 34525909]
[11]
Nascimento, I.J.S.; de Aquino, T.M.; da Silva-Júnior, E.F. The new Era of drug discovery: The power of computer-aided drug design (CADD). Lett. Drug Des. Discov., 2022, 19(11), 951-955.
[http://dx.doi.org/10.2174/1570180819666220405225817]
[12]
dos Santos Nascimento, I.J.; de Aquino, T.M.; da Silva-Júnior, E.F. Drug repurposing: A strategy for discovering inhibitors against emerging viral infections. Curr. Med. Chem., 2021, 28(15), 2887-2942.
[http://dx.doi.org/10.2174/1875533XMTA5rMDYp5] [PMID: 32787752]
[13]
Wu, Y.; Wang, B.; Wang, J.; Qi, S.; Zou, F.; Qi, Z.; Liu, F.; Liu, Q.; Chen, C.; Hu, C.; Hu, Z.; Wang, A.; Wang, L.; Wang, W.; Ren, T.; Cai, Y.; Bai, M.; Liu, Q.; Liu, J. Discovery of 2-(4-chloro-3-(trifluoromethyl)phenyl)- N -(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a novel orally available potent inhibitor against broad-spectrum mutants of c-KIT kinase for gastrointestinal stromal tumors. J. Med. Chem., 2019, 62(13), 6083-6101.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00280] [PMID: 31250638]
[14]
Liu, X.; Wang, B.; Chen, C.; Qi, Z.; Zou, F.; Wang, J.; Hu, C.; Wang, A.; Ge, J.; Liu, Q.; Yu, K.; Hu, Z.; Jiang, Z.; Wang, W.; Wang, L.; Wang, W.; Ren, T.; Bai, M.; Liu, Q.; Liu, J. Discovery of (E)-N1-(3-fluorophenyl)- N3 -(3-(2-(pyridin-2-yl)vinyl)-1 H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a novel c-KIT T670I mutant selective kinase inhibitor for gastrointestinal stromal tumors (GISTs). J. Med. Chem., 2019, 62(10), 5006-5024.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00176] [PMID: 31046271]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy